O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Pharmaceutical Sales - Strategic Account Liaison, Rare Neurology

Full-TimeUpdated on 10/23/2026
$157.7k - $252.3k+ Incentive opportunity
Senior, Expert
Bachelor's
Remote in USA
RemoteRemote within the United States; employee must reside in the assigned region. Must reside in Region
Sales & Account ManagementAccount Management

About the job

Requirements
  • Experience understanding complex disease states and the ability to quickly learn and articulate complex clinical data and outcomes.
  • Experience developing strategic account plans by mining and connecting insights from diverse data sources, customer feedback, and market intelligence to drive regional strategy and execution.
  • Experience with products or disease states where the patient journey involves many physicians, specialties, and sites of care before a definitive diagnosis.
  • Ability to thrive without a highly prescriptive operating model to identify, validate, and document local referral networks, including primary treaters, secondary treaters, and referral patterns for amyotrophic lateral sclerosis.
  • A valid U.S. driver’s license and a driving record in compliance with company standards.
  • A bachelor's degree.
  • A minimum of 8 years of experience in biotech or pharmaceutical commercial field strategic roles; 10+ years is preferred.
  • Experience in new product launches.
  • Center of Excellence and integrated delivery network navigation, including key opinion leader engagement.
  • Rare or ultra-rare disease experience.
  • Cross-functional field team coordination.
  • A proven track record of success demonstrated by consistent high ranking in the top 30% for a minimum of 2 years, achievement awards, or similar evidence.
  • The employee must reside in the assigned region.
  • Advanced clinical degrees such as a Bachelor of Science in Nursing or registered nurse qualification are prioritized but are not required.
  • Ability to make decisions considering long-term impacts to customers, patients, employees, and the business.
  • Ability to maintain an ongoing focus on the needs of customers and key stakeholders.
  • Ability to communicate with logic, clarity, and respect and influence at all levels.
  • Ability to seek and value others’ perspectives and build diverse partnerships toward common goals.
  • Ability to take an active role in professional development.
Responsibilities
  • Educate health care providers and other stakeholders on disease-state awareness, screening and diagnostic pathways, and the need to prioritize and treat appropriate patients.
  • Identify, develop, and maintain relationships with health care providers and key opinion leaders, demonstrating clinical acumen and serving as a credible resource.
  • Create a positive prescribing experience through clear articulation and diligent follow-through on access and patient support programs.
  • Participate in conferences, congresses, and scientific meetings to educate stakeholders about rare neurology diseases and treatments.
  • Navigate and engage stakeholders within amyotrophic lateral sclerosis Centers of Excellence to understand roles and responsibilities, obtain key contacts, document process flows, and advance company objectives.
  • Navigate treatment logistics, including site-of-care considerations, patient onboarding, and therapy initiation barriers.
  • Use experience with hospital purchasing, coding, and reimbursement procedures to identify account process flows, articulate access specifics, and partner with Market Access and Patient Support to compliantly remove barriers to therapy.
  • Map patient journeys, identify barriers to earlier recognition, specialist referral, genetic testing, genetic counseling, and connection to treatment-capable centers, and formulate solutions and relationships to address those gaps.
  • Partner with cross-functional teammates, including Thought Leader Liaisons, Medical Science Liaisons, case managers, and leadership, to understand and address customer and patient needs and maintain high customer-experience standards.
  • Engage proactively with others, support healthy discussions, adapt communication and approach to others’ emotions, and drive alignment and business objectives.
  • Demonstrate tenacity and innovative thinking while collaboratively building consensus among stakeholders.
  • Use company platforms and technology to share account contact information and document integrated delivery network process flows and community referral patterns.
  • Participate in meetings and training programs to understand brand strategy, messaging, disease state, and customer engagement tactics and implement them in the assigned region.
  • Certify on approved clinical resources, messaging, business acumen training, compliance, company policies, and applicable health care provider and patient engagement policies.
  • Stay focused on strategic objectives, maintain high performance standards, and take an active role in leading change.
Desired Qualifications
  • Background in rare neurology, chimeric antigen receptor T-cell therapy, or gene therapy account management is strongly preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.